Abstract:BackgroundCitrulline post-translational modification of proteins is mediated by protein arginine deiminase (PADI) family members and has been associated with autoimmune diseases. The role of PADI-citrullinome in immune response in cancer has not been evaluated. We hypothesized that PADI-mediated citrullinome is a source of neoantigens in cancer that induces immune response.MethodsProtein expression of PADI family members was evaluated in 196 cancer cell lines by means of indepth proteomic profiling. Gene expression was assessed using messenger RNA data sets from The Cancer Genome Atlas. Immunohistochemical analysis of PADI2 and peptidyl-citrulline was performed using breast cancer tissue sections. Citrullinated 12–34-mer peptides in the putative Major Histocompatibility Complex-II (MHC-II) binding range were profiled in breast cancer cell lines to investigate the relationship between protein citrullination and antigen presentation. We further evaluated immunoglobulin-bound citrullinome by mass spectrometry using 156 patients with breast cancer and 113 cancer-free controls.ResultsProteomic and gene expression analyses revealed PADI2 to be highly expressed in several cancer types including breast cancer. Immunohistochemical analysis of 422 breast tumor tissues revealed increased expression of PADI2 in ER− tumors (p<0.0001); PADI2 protein expression was positively correlated (p<0.0001) with peptidyl-citrulline staining. PADI2 expression exhibited strong positive correlations with a B cell immune signature and with MHC-II-bound citrullinated peptides. Increased circulating citrullinated antigen–antibody complexes occurred among newly diagnosed breast cancer cases relative to controls (p=0.0012).ConclusionsAn immune response associated with citrullinome is a rich source of neoantigens in breast cancer with a potential for diagnostic and therapeutic applications.

PADs in cancer: Current and future

PAD4 and Its Inhibitors in Cancer Progression and Prognosis

Role of protein deimination in cardiovascular diseases: potential new avenues for diagnostic and prognostic biomarkers

Progression on Citrullination of Proteins in Gastrointestinal Cancers

Structure–Activity Relationship of PAD4 Inhibitors and Their Role in Tumor Immunotherapy

Peptidylarginine deiminases 4 as a promising target in drug discovery

Protein citrullination: inhibition, identification and insertion

Peptidylarginine deiminase (PAD): A promising target for chronic diseases treatment

The Role of Citrullination Modification in CD4+ T Cells in the Pathogenesis of Immune-Related Diseases

Neutrophil-derived PAD4 induces citrullination of CKMT1 exacerbates mucosal inflammation in inflammatory bowel disease

PAD-mediated citrullination is a novel candidate diagnostic marker and druggable target for HPV-associated cervical cancer

Colorectal cancer liver metastatic growth depends on PAD4-driven citrullination of the extracellular matrix

Protein Citrullination As a Source of Cancer Neoantigens.

The Critical Roles of Activated Stellate Cells-Mediated Paracrine Signaling, Metabolism and Onco-Immunology in Pancreatic Ductal Adenocarcinoma

Endogenous PAD4 in Breast Cancer Cells Mediates Cancer Extracellular Chromatin Network Formation and Promotes Lung Metastasis

Peptidylarginine Deiminases—Roles in Cancer and Neurodegeneration and Possible Avenues for Therapeutic Intervention via Modulation of Exosome and Microvesicle (EMV) Release?

PD-1/PD-L1 pathway: current researches in cancer.

Protein arginine deiminase 2 binds calcium in an ordered fashion: implications for inhibitor design.

Emerging roles of protein palmitoylation and its modifying enzymes in cancer cell signal transduction and cancer therapy

Reciprocal regulation of Th2 and Th17 cells by PAD2-mediated citrullination.

New Molecular Targets for Therapy